Skip to main content
Fig. 3 | Acta Neuropathologica Communications

Fig. 3

From: Cyclosporin promotes neurorestoration and cell replacement therapy in pre-clinical models of Parkinson’s disease

Fig. 3

Cyclosporin treatment improves graft survival and reduces pathology in ungrafted AAV-α-synuclein lesioned rats. a Motor function was assessed before injection of an AAV-α-synuclein (−8 weeks time-point), before transplantation (0 week time-point), and 6 and 12 weeks post-transplantation using the amphetamine-induced rotation test. Data are expressed as mean ± SEM (n = 8-10 per group). # P < 0.05 compared to the respective vehicle treated group, ***P < 0.001 compared to the respective sham control group (t-test). b-c Assessment of graft volume (b) and quantification of the number of graft-derived TH-positive cells (c) showed increased survival of the transplant in the CsA treated group. Data are expressed as mean ± SEM (n = 8-10 per group). *P < 0.05 (t-test). d Striatal sections from all experimental groups were stained for TH to analyze the extent of the lesion and the survival of grafted dopamine neurons. Scale bar: 1.5 mm. e Western blot analysis of the striatal levels of human α-synuclein and TH in AAV-α-synuclein + sham rats treated with CsA (i.p., 10 mg/kg, daily) or vehicle. Data are expressed as mean ± SEM (n = 6 per group). *P < 0.05 (t-test)

Back to article page